IP Library › Granted Patent US 7,851,195
Granted Patent B2
US 7,851,195 · App. 12/214,588 · Granted Dec 14, 2010

High-efficiency wild-type-free AAV helper functions

Assignee: Genzyme Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,851,195
App. No.
12/214,588
Granted
Dec 14, 2010
Kind
B2
Abstract

The present invention provides methods and compositions for producing high titer, wild-type-free preparations of recombinant AAV (“rAAV”) virions. The compositions of the present invention include novel nucleic acids encoding AAV helper functions and AAV helper function vectors. The present invention also includes host cells transfected by the claimed nucleic acids, methods of using the claimed vectors, and rAAV virions produced by such methods.

Claims (45)

1. A method of producing recombinant AAV (rAAV) virions comprising:

introducing into a suitable host cell

(a) an AAV vector;

(b) an AAV helper function vector, wherein the helper function vector comprises a nucleic acid molecule which encodes one or more AAV helper functions, said nucleic acid molecule comprising:

an AAV rep coding region;

an AAV cap coding region; and

a nucleotide sequence comprising a modified AAV p5 promoter region, such that the modified AAV p5 promoter region no longer functions in transcription initiation; and

(c) accessory functions upon which AAV is dependent for replication; and

culturing the host cell to produce rAAV virions.

2. A host cell comprising

(a) an AAV vector;

(b) an AAV helper function vector, wherein the helper function vector comprises a nucleic acid molecule which encodes one or more AAV helper functions, said nucleic acid molecule comprising:

an AAV rep coding region;

an AAV cap coding region; and

a nucleotide sequence comprising a modified AAV p5 promoter region, such that the modified AAV p5 promoter region no longer functions in transcription initiation; and

(c) accessory functions upon which AAV is dependent for replication.

3. The host cell of claim 2 , wherein the accessory functions comprise accessory function genes.

4. A method of producing recombinant AAV (rAAV) virions comprising:

introducing into a suitable host cell

(a) an AAV vector;

(b) an AAV helper function vector, wherein the helper function vector comprises a nucleic acid molecule which encodes one or more AAV helper functions, said nucleic acid molecule comprising:

an AAV rep coding region;

an AAV cap coding region; and

a nucleotide sequence comprising a modified AAV p5 promoter region, wherein the modified p5 promoter region lacks an intact TATA box; and

(c) accessory functions upon which AAV is dependent for replication; and

culturing the host cell to produce rAAV virions.

5. A host cell comprising

(a) an AAV vector;

(b) an AAV helper function vector, wherein the helper function vector comprises a nucleic acid molecule which encodes one or more AAV helper functions, said nucleic acid molecule comprising:

an AAV rep coding region;

an AAV cap coding region; and

a nucleotide sequence comprising a modified AAV p5 promoter region, wherein the modified p5 promoter region lacks an intact TATA box; and

(c) accessory functions upon which AAV is dependent for replication.

6. The host cell of claim 5 , wherein the accessory functions comprise accessory function genes.

7. The host cell of claim 5 , such that the modified AAV p5 promoter region is situated 3′ relative to the rep coding region.

8. A method of producing recombinant AAV (rAAV) virions comprising:

introducing into a suitable host cell

(a) an AAV vector;

(b) an AAV helper function vector, wherein the helper function vector comprises a nucleic acid molecule which encodes one or more AAV helper functions, said nucleic acid molecule comprising:

an AAV rep coding region;

an AAV cap coding region; and

a nucleotide sequence comprising a modified AAV p5 promoter region, wherein the modified p5 promoter region lacks an intact TATA box and the nucleotide sequence is arranged such that the modified AAV p5 promoter region is situated 3′ relative to the rep coding region; and

(c) accessory functions upon which AAV is dependent for replication; and

culturing the host cell to produce rAAV virions.

9. The host cell of claim 5 , such that the modified AAV p5 promoter region is situated 3′ relative to the cap coding region.

Continuity (8)
Continuation 1128335700 · Nov 18, 2005
Continuation 1007430200 · Feb 11, 2002
Continuation 0945008300 · Nov 29, 1999
Continuation 0914327000 · Aug 28, 1998
Continuation In Part 0910770800 · Jun 30, 1998
Continuation In Part 0868864800 · Jul 29, 1996
Continuation In Part 0851079000 · Aug 3, 1995
Related Publication 20090017542A1 · Jan 15, 2009